Trial site
London
London, London, City of NW1 2BU, United KingdomNot linked to an institution yet
- 18running trials
- 6closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 28 trials
- Phase 11 trial
- Phase 1/21 trial
- Status
- Active, not recruiting9 trials
- Recruiting8 trials
- Completed5 trials
- Enrolling by invitation1 trial
- Terminated1 trial
- Lead sponsor
- Sanofi20 trials
- Genzyme, a Sanofi Company2 trials
- Bioverativ, a Sanofi company1 trial
- Sanofi Pasteur, a Sanofi Company1 trial
Running trials
Recruiting
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
NCT07688213· Phase 2· Sanofi· Source
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07185009· Phase 3· Sanofi· Source
Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031· Phase 2· Sanofi· Source
Recruiting
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234· Phase 1/2· Sanofi· Source
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931· Phase 3· Sanofi· Source
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222· Phase 3· Sanofi· Source
Recruiting
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865· Phase 3· Sanofi· Source
Active, not recruiting
A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
NCT06975722· Phase 2· Sanofi· Source
Recruiting
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
NCT06958536· Phase 2· Sanofi· Source
Active, not recruiting
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360· Phase 3· Sanofi· Source
Active, not recruiting
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319· Phase 2· Sanofi· Source
Enrolling by invitation
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315· Phase 3· Sanofi· Source
Active, not recruiting
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777· Phase 2· Sanofi· Source
Active, not recruiting
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
NCT05280548· Phase 3· Sanofi· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
NCT05222906· Phase 3· Sanofi· Source
Active, not recruiting
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
NCT04910776· Phase 3· Sanofi· Source
Active, not recruiting
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
NCT04644575· Phase 3· Bioverativ, a Sanofi company· Source
Active, not recruiting
A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa
NCT03019406· Phase 2· Genzyme, a Sanofi Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error